Skip to main content
9409046853
e-ISSN: 2394-2967
British Journal of Medical and Health Research

British Journal of Medical and Health Research

British Journal of Medical and Health Research

BJMHR – British Journal of Medical & Health Research

BJMHR is an international, peer-reviewed open access journal publishing rigorously reviewed research in medicine, pharmacy, clinical research, and health sciences. Established in 2014, BJMHR provides researchers worldwide with a transparent and efficient platform to share high-quality research and advance scientific knowledge.. e-ISSN: 2394-2967

.

📢 Latest Update: 🔔 Call for Papers 2026 | BJMHR Now Accepting Manuscripts for September 2026 Issue | Peer-Reviewed | Open Access | Fast Review in 5–7 Days | Submit Now

📢 Latest Update: 🔔 Call for Papers 2026 | BJMHR Now Accepting Manuscripts for September 2026 Issue | Peer-Reviewed | Open Access | Fast Review in 5–7 Days | Submit Now

Important Journal Details

Title:
British Journal of Medical and Health Research
Journal Short Name:
BJMHR
e-ISSN (Online):
2394-2967
Year of Establishment:
2014
Frequency of the Publication:
Monthly (1 Issue / month)
Publication Format:
Online
Publication URL:
https://bjmhr.com
Related Subject:
MedicalBiomedical ResearchClinical Medicine and Research...+ View more
Language:
English
Editor-in-Chief:
Dr J S Patel
Editorial Board:
Click Here →

Download Forms & Formats

Download Hub

Journal Features

Rigorous Peer Review

Every submission is independently evaluated by subject-matter experts before acceptance, keeping our academic standards high

Global Reach

Authors from 195+ countries have published with us, and their work reaches researchers, clinicians, and academics worldwide.

Rapid Publication

An efficient review process in our peer reviewed medical journal ensures fast publication of accepted manuscripts while maintaining high quality and rigorous academic standards.

Open Access

All published papers in our open access medical journal are freely available online, ensuring maximum visibility, accessibility, and global impact for your research.

Publication Procedure

1

Prepare Manuscript

Format your paper according to our guidelines

View Guidelines
style="fill: var(--journal-600);"
2

Submit Paper

Upload your manuscript through our system

Submit Now
3

Peer Review

Your paper undergoes expert evaluation

Learn More
4

Publication

Accepted papers are published worldwide

View Publications
View All Issues
Cover image for Non-Hodgkin Lymphoma Mimicking an Antibioma Following Dental Extraction

Non-Hodgkin Lymphoma Mimicking an Antibioma Following Dental Extraction

Jaliya moitheen.R, Dr.Mijil Anand Justin

Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoid malignancies with clinical behaviour ranging from indolent to highly aggressive. These neoplasms arise from lymphoid cells at different stages of differentiation, and their biological characteristics reflect their cellular origin. Intraoral NHL is uncommon and may involve either the jaw bones or the soft tissues of the oral cavity. We report the case of a 54-year-old man who presented with persistent buccal space swelling following extraction of the mandibular right second molar (tooth 47) for presumed odontogenic infection. Despite antibiotic therapy, the swelling progressively increased in size and was associated with the development of lower-lip paresthesia. An initial clinical diagnosis of antibioma was made; however, the persistence and progression of the lesion prompted further investigation. Histopathological examination and immunohistochemical analysis established a diagnosis of diffuse large B-cell lymphoma (DLBCL). This case highlights the importance of considering malignant disease in the differential diagnosis of persistent or progressive orofacial swellings, particularly when presumed odontogenic lesions fail to respond to appropriate treatment or are accompanied by neurosensory disturbances.

Cover image for Platinum Plus Immunotherapy Versus Platinum Alone in Triple-Negative Breast Cancer: A Systematic Review

Platinum Plus Immunotherapy Versus Platinum Alone in Triple-Negative Breast Cancer: A Systematic Review

Dr. Animesh Kumar Mishra, Dr. Parmita Roy, Dr. Silky Kumari, Shubhartha Kayal

Triple-negative breast cancer (TNBC) represents approximately 15–20% of all breast cancers and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. TNBC is associated with aggressive clinical behavior , higher rates of visceral metastasis, earlier recurrence, and poorer overall prognosis compared to other breast cancer subtypes. Cytotoxic chemotherapy has historically remained the mainstay of systemic treatment. Among available agents, platinum compounds such as carboplatin and cisplatin have demonstrated particular activity because TNBC frequently exhibits defects in homologous recombination DNA repair pathways, including BRCA1/2 dysfunction. In recent years, immune checkpoint inhibitors against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have emerged as promising therapeutic strategies. Combining immunotherapy with platinum-based chemotherapy may enhance antitumor immunity and improve outcomes. Objective To conduct a systematic review of existing evidence that contrasts the use of platinum combined with immunotherapy against platinum alone in individuals with early-stage and metastatic TNBC, with an emphasis on evaluating efficacy, survival rates, pathological complete response, and safety. Results Significant trials such as KEYNOTE-355, KEYNOTE-522, IMpassion130, IMpassion031, GeparNuevo, NeoTRIPaPDL1, along with various pooled analyses, have shown enhanced pathological complete response (pCR), progression-free survival (PFS), event-free survival (EFS), and overall survival (OS) in specific TNBC groups receiving platinum combined with immunotherapy, as opposed to chemotherapy alone. The advantages were particularly evident in PD-L1-positive metastatic TNBC and early-stage II–III TNBC. Nonetheless, the incidence of immune-related adverse events was higher in the arms receiving combination therapy. Conclusion Conclusion present data indicate that combining platinum with immunotherapy offers a more effective treatment approach than using platinum by itself for carefully chosen patients with TNBC. It remains crucial to select patients based on biomarkers and to manage toxicity effectively.

Cover image for Salvaging Hopeless Teeth by Hemisection: Two Case Reports with 1-Year Follow-up

Salvaging Hopeless Teeth by Hemisection: Two Case Reports with 1-Year Follow-up

Nancy Budakoti, Afaf Zia, Aisha Samreen, Adeela Majid

Background: Endo-periodontal lesions (EPL) present considerable diagnostic and therapeutic challenges. Hemisection, when appropriately indicated, serves as a conservative alternative to extraction in multirooted teeth. Case Presentation: This report presents two separate cases in which mandibular molars exhibit EPL with localized root damage. Following comprehensive endodontic and periodontal evaluation, the non-salvageable distal root was resected, and the remaining mesial root was preserved. Treatment included nonsurgical root canal therapy, full-thickness flap surgery, debridement, hemisection and socket preservation using demineralized freeze-dried bone allograft (DFDBA), platelet-rich fibrin (PRF), and a collagen membrane. Both cases were rehabilitated with a fixed partial denture. 12-month postoperative follow-up of both cases demonstrated successful clinical and radiographic outcomes, including stable periodontal parameters and restored function. Conclusion: Hemisection remains a viable option for preserving function and natural dentition in selected cases of EPL with localized root damage.

Publication Procedure

Learn about our 4-step publication process

Author Guidelines

Review requirements before submitting

Submit Article

Ready to submit your research?

554
Published Articles
1,523
Active Researchers
195
Countries
4.2
Impact Factor
Whatsapp